SCA
GERM

Snowden Capital Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Snowden Capital Advisors’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$7K – 2157
2021
Q4 		$7K Buy
+200
New +$7.5K ﹤0.01% 1628

Other funds holding GERM

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Snowden Capital Advisors's GERM Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2022, closing a stake of 200 shares — an estimated $7K sold.

Snowden Capital Advisors first reported a position in GERM in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 28 funds tracked by Wall St. Rank hold GERM as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 200 Amplify Treatments, Testing and Advancements ETF shares in Q1 2022, an estimated $7K.
  • Snowden Capital Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $7K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.